U.S. License Holder:
Eli Lilly and Co.
Date of License:
September-18-2014
Last Update:
Sep-30-2024
FDA-Approved Indications
TRULICITY (dulaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated:
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus;
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.